MicroPort Scientific : ® Endovascular Attends CEC 2017

Beijing, China - MicroPort Endovascular (Shanghai) Co., Ltd. ('MicroPort Endovascular') recently attended the 10th China Endovascular Course & 2017 National Continuing Education Program for Vascular Surgeons ('CEC 2017') that was held in the Beijing National Convention Center, to broadcast surgeries as well as host satellite meetings and academic symposiums with experts in attendance. The CEC 2017 was hosted by Beijing Anzhen Hospital of Capital Medical University, Chinese PLA General Hospital, Zhongshan Hospital of Fudan University, and Cross-Straits Medicine Exchange Association. It aims to enhance the development of basic medicine, standardize clinical operation, follow up the results of major studies and researches, and display the latest advancement in the vascular disease treatment.

During the conference, MicroPort Endovascular demonstrated the clinical performance of its products by surgical videos. Professor Wei Guo and Professor Ye Wu of Chinese PLA General Hospital reviewed a surgery in which Castor Branched Aortic Stent-Graft System ('Castor') was used to treat chronic aortic dissection. The patient was admitted with chest pain and was diagnosed as chronic aortic dissection. The preoperative CT showed that the aberrant right subclavian artery passed through the back of esophagus and trachea and finally entered into the right thoracic cavity. The tear was located at the beginning part of the right subclavian artery and the left subclavian artery was normal. The experts selected Castor branched stent to restore the aberrant right subclavian artery in endovascular method. Castor branched stent was imported and released in standard process. The postoperative imaging showed the stent was in good form and the tear was completely covered. Professor Guo said: 'Castor is in standardized product design and can meet various anatomical morphologies. Therefore, it is necessary to use preoperative measuring software to have a careful evaluation and choose the appropriate specifications.' Professor Xiaohui Ma and Professor Yongle Xu of Chinese PLA General Hospital reviewed a surgery using drug coated balloon to treat long superficial femoral arterial occlusion. In this case, Reewarm™ Peripheral Balloon Dilation Catheter ('Reewarm™') was used to dilate the superficial femoral artery and achieved a good result. Professor Weiguo Fu of Zhongshan Hospital of Fudan University released the results of one-year pre-market clinical study of Minos™ Ultra Low-Profile AAA Stent-Graft System ('Minos™'). He said: 'Minos™ achieved good result in treating infrarenal abdominal aortic aneurysm ('AAA') at one year, and we are waiting for more evidence to support its long-term treatment effect. Besides, Minos™ has unique advantages in treating complex type AAA, especially when the introduction artery is narrow, or the aneurysmic neck is tortuous or short.'

Afterwards, MicroPort Endovascular hosted a satellite meeting, in which Professor Changwei Liu of Peking Union Medical College Hospital was invited as the chairman, and Professor Wei Ye of Peking Union Medical College Hospital, Qingsheng Lu of Changhai Hospital, Professor Jue Yang of Zhongshan Hospital of Fudan University, and Professor Xinwu Lu of Shanghai Ninth Hospital of Shanghai Jiaotong University were invited as the guest speakers to share clinical studies and their clinical experience in Castor, Reewarm PTX and Minos™ with the attendees. Professor Lu shared the tips of using Castor. He said: 'As the world's first branched aortic stent-graft system, Castor will exert great impact on China's vascular surgery industry.' Castor adopts unibody design to achieve revascularization of left subclavian artery. It has good long-term anti-fatigue performance and low risk of endoleak and displacement. At the same time, it adopts standardized design, conforming to various morphologies. It also features dual-access delivery system design, and crossing the arch with soft sheath and pulling wire release mechanism ensure its accurate positioning and fast release. Professor Wei Ye released the outcome of pre-market clinical study of Reewarm PTX. He said, Reewarm PTX is mainly indicated for the treatment of stenosis of femoral and popliteal artery and occlusive lesion. It uses ultrasonic spraying technology to ensure stable drug-loading. With the proprietary coating formula, the drug enters into the blood under the protection of water-soluble carrier. After the carrier is dissolved, the drug particles are polymerized under the action of static electricity and are not easy to fall off, which will release rapidly after the balloon expands. Compared to similar products in the market, Reewarm PTX has more stable drug attaching. According to periodic statistics, the six-month LLL of Reewarm PTX is similar to that of imported products and is much lower compared to naked balloons. The safety and efficacy of Reewarm PTX still needs to be verified with more clinical data and long-term follow-up. Professor Jue Yang delivered a report on pre-market clinical studies of Minos™. He said, the Minos™ clinical trial in Zhongshan Hospital achieved good results with 100% 30-day technical success rate, 100% instrument success rate, 100% 12-month clinical success rate and there is no stent migration or occlusion. But its long-term efficacy needs to be proved with further follow-up. Professor Xinwu Lu introduced the latest advancement of infrapopliteal drug coated balloon dilation catheter. He said, the clinical data of launched and on-going infrapopliteal drug coated balloon dilation catheter show, on the one hand, the inclusion criterion is too strict to reflect the clinical application status of the real world, and on the other hand, the result is not ideal if looking into some safety data such as the limb-protection rate and mortality rate. Given the above-mentioned clinical dilemma, MicroPort Endovascular launched an open FIM research in small sample size without strict inclusion criterion for its infrapopliteal drug coated balloon dilation catheter in Shanghai Ninth People's Hospital. Since it is an open clinical trial, distribution of the selected cases is more consistent with the real world. Up to date, the clinical study has achieved satisfactory outcome.

MicroPort Endovascular hosted two symposiums respectively regarding the advancement of thoracic aortic aneurysm TEVAR treatment as well as case studies and simulator demonstration of Castor. With the combination of academic exchanges and physical simulations, the two symposiums attracted many experts to exchange ideas on Castor, Hercules™-T Low Profile Stent-Graft and Talos™ Thoracic Stent Graft System. Some of them had in-depth discussion with our R&D staff in terms of design features and surgical techniques based on their own clinical experience. MicroPort Endovascular President Zhenghua Miao said: 'We hope to take advantage of academic platforms such as the CEC to enhance communication with physicians to keep improving our products based on their clinical needs, and thereby benefit more physicians and patients.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:

Amanda Zhang Corporate Culture & Public Relations Director Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-6989 Email: [e-mail]